Tumorstammzellen als therapeutisches Ziel der Tumortherapie von morgen
[Cancer stem cells as the therapeutic target of tomorrow]
Jazyk němčina Země Rakousko Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
26943922
DOI
10.1007/s10354-016-0446-1
PII: 10.1007/s10354-016-0446-1
Knihovny.cz E-zdroje
- Klíčová slova
- Cancer stem cells, Cancer therapy, Combination therapy, Drug repurposing,
- MeSH
- individualizovaná medicína MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- nádorové kmenové buňky účinky léků MeSH
- nádory farmakoterapie MeSH
- přehodnocení terapeutických indikací léčivého přípravku MeSH
- protinádorové látky terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- protinádorové látky MeSH
The concept of hierarchical organization of tumour cell population, with cancer stem cells positioned at the apex of the cell hierarchy, can explain at least some crucial aspects of biological and clinical behaviour of cancer, like its propensity to relapse as well as the development of therapeutic resistance. The underlying biological properties of cancer stem cells are crucially dependent on various signals, inhibition of which provides an attractive opportunity to attack pharmacologically cancer stem cells. Currently, a lot of such stemness-inhibitors undergo various phases of clinical testing. Interestingly, numerous old drugs that are in routine use in human and veterinary medicine for non-oncological indications appear to be able to specifically target cancer stem cells as well. As cancer stem cells, at least for most tumours, represent usually only a minor tumour cell fraction, it is quite probable that the main focus of the clinical use of the stemness inhibitors would consist in their rational combinations with traditional anticancer treatment modalities. A highly important goal for the future research is to identify reliable and clinically applicable predictive markers that would allow to apply these novel anticancer drugs on the individual basis within the context of personalized medicine.
Zobrazit více v PubMed
Cancer Cell. 2012 Mar 20;21(3):283-96 PubMed
Nat Rev Cancer. 2005 Sep;5(9):744-9 PubMed
J Natl Cancer Inst. 2011 Jul 6;103(13):1018-36 PubMed
Nature. 2013 Sep 19;501(7467):328-37 PubMed
Praxis (Bern 1994). 2013 Jan 30;102(3):139-46 PubMed
Clin Transl Med. 2013 Jan 17;2(1):3 PubMed
Cell. 2012 Jun 8;149(6):1284-97 PubMed
Cell Stem Cell. 2014 Mar 6;14(3):275-91 PubMed
Nat Rev Clin Oncol. 2015 Aug;12(8):445-64 PubMed
Carcinogenesis. 2014 Mar;35(3):692-702 PubMed
Nat Rev Drug Discov. 2014 Jul;13(7):497-512 PubMed
Cell. 2009 Aug 21;138(4):645-659 PubMed
Nat Med. 2014 Oct;20(10):1199-205 PubMed
Biomaterials. 2014 Jan;35(3):1096-108 PubMed
Cell Stem Cell. 2015 Mar 5;16(3):225-38 PubMed
Dtsch Med Wochenschr. 2007 Aug;132(31-32):1629-32 PubMed
Br J Cancer. 2011 May 10;104(10):1564-74 PubMed
Cell. 2008 May 16;133(4):704-15 PubMed
Wien Klin Wochenschr. 2010 Jul;122(13-14):423-36 PubMed
Oncotarget. 2014 Jun 15;5(11):3743-55 PubMed
Br J Cancer. 2011 Sep 6;105(6):796-806 PubMed
Nat Med. 2013 Nov;19(11):1410-22 PubMed
Cell Stem Cell. 2010 Aug 6;7(2):150-61 PubMed
Future Med Chem. 2014 Sep;6(14):1567-85 PubMed
Biochemistry. 2009 Nov 3;48(43):10267-74 PubMed
Arch Pharm Res. 2015 Sep;38(9):1617-26 PubMed
Profiles Drug Subst Excip Relat Methodol. 2005;32:67-96 PubMed
Science. 2013 Feb 1;339(6119):543-8 PubMed
J Cell Biochem. 2009 Apr 1;106(5):745-9 PubMed
Neoplasma. 2012;59(6):700-7 PubMed
Cell Death Dis. 2014 Feb 06;5:e1051 PubMed
Stem Cells Transl Med. 2015 Sep;4(9):1028-32 PubMed
Anticancer Agents Med Chem. 2015;15(5):575-91 PubMed
Oncotarget. 2012 Oct;3(10 ):1112-23 PubMed
Cancer Lett. 2014 Jul 10;349(1):8-14 PubMed
